Comparative Pharmacology
Head-to-head clinical analysis: MECAMYLAMINE HYDROCHLORIDE versus RAUWILOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECAMYLAMINE HYDROCHLORIDE versus RAUWILOID.
MECAMYLAMINE HYDROCHLORIDE vs RAUWILOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (nAChRs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.
Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.
Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.
2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12-24 hours; clinically, this allows once or twice daily dosing but requires dose adjustment in renal impairment.
Terminal elimination half-life is approximately 10–12 hours. Clinical context: Requires twice-daily dosing for sustained antihypertensive effect; steady-state achieved in 2–3 days.
Renal: 50-70% unchanged; biliary/fecal: minimal (less than 5%)
Primarily renal excretion of metabolites; ~60–80% of a dose is eliminated in urine as metabolites, with <1% as unchanged drug. Biliary/fecal excretion accounts for ~15%.
Category C
Category C
Antihypertensive
Antihypertensive